




Advancing Therapeutics.  
Improving Lives.



September 3, 2015

Dr Raju Kalidindi  
Laurus Labs Private Limited  
2<sup>nd</sup> Floor, Serene Chambers  
Road No. 7, Banjara Hills  
Hyderabad  
500034 India

**RE: TAF Combination Products**

To Whom it May Concern:

Reference is made to that certain Amended and Restated License Agreement between Laurus Labs Private Limited (“you”), the Medicines Patent Pool Foundation and Gilead Sciences, Inc. (“Gilead”), dated as of September 11, 2014, and to any subsequent modification thereof (the “License Agreement”). All capitalized terms used in this letter but not defined herein shall have the meanings assigned to such terms in the License Agreement.

This letter is to clarify that Section 2.5(b)(ii) of the License Agreement is not intended to prohibit you from manufacturing or selling any TAF Combination Products following Gilead’s receipt of Marketing Approval for the TAF Quad. Accordingly, following Gilead’s receipt of Marketing Approval by the FDA for the TAF Quad, Gilead hereby agrees that your manufacture or sale of any TAF Combination Product (including without limitation the TAF Quad) in accordance with the terms of the License Agreement will not constitute a breach of Section 2.5(b)(ii) of the License Agreement.

If you have any further questions, please contact Kushendra Chaudhary at [kchaudhary@medicinespatentpool.org](mailto:kchaudhary@medicinespatentpool.org).

Kind Regards,

Clifford Samuel  
Senior Vice President  
Access Operations & Emerging Markets  
Gilead Sciences, Inc.

Greg Perry  
Executive Director  
Medicines Patent Pool Foundation